PMC2394239_01
Case 4: Brain CT-scan at baseline (A) and after 3 months of ZD1839 therapy (B). Brain metastasis from NSCLC responding to ZD 1839 therapy. This patient has been pretreated with three lines of chemotherapy including platinum and taxanes, and received ZD 1839 after whole-brain radiotherapy failure.
89-6601116f1.jpg
PMC2394239_01_89-6601116f1.jpg
fig1
After 3 months of ZD 1839 therapy, all the patients had a partial response both in the brain and in the extracranial sites (Figure 1).